Why Theradaptive’s OsteoAdapt could disrupt the $2bn spinal biologics market in 2026
ATEC secures U.S. rights to Theradaptive’s OsteoAdapt. Find out what this deal changes for spinal biologics in 2026 and beyond.
Can Datasea’s acoustic BCI tech unlock real-world stroke rehab and assistive device control?
Datasea unveils two acoustic-powered BCI innovations targeting rehab robotics and assistive communication. Find out what this means for the future of healthcare AI.
Medtronic’s MiniMed Go cleared by FDA: Can smart MDI finally close the algorithm gap in diabetes care?
Medtronic’s MiniMed Go earns FDA clearance. Learn how it could reshape insulin injection therapy by combining smart pens, CGM insights, and dose algorithms.
Why 10x Genomics is betting on CLIA lab certification to advance spatial diagnostics in oncology
Find out how 10x Genomics and Dana-Farber aim to transform cancer diagnostics using spatial biology and single cell profiling for real-world clinical decisions.
Pierre Fabre and Iktos partner on AI-designed small-molecule cancer therapies
Pierre Fabre joins forces with Iktos to discover AI-designed oncology drugs. Find out what this means for cancer R&D, regulatory strategy, and pipeline speed.
Treatment beyond progression? Zenocutuzumab data could shift standards in NRG1+ pancreatic cancer
Find out how zenocutuzumab could change treatment strategies in NRG1+ pancreatic cancer after progression. Explore new ASCO GI 2026 data today.
M&G backs bit.bio with $50m Series C to accelerate NAMs and AI-ready cell models
bit.bio raised $50M to expand its human cell programming platform for toxicology and AI model training. Find out why investors are backing NAMs now.
Can Ventaris Surgical’s $30m-backed system solve the biggest gap in kidney stone treatment?
Ventaris Surgical raises $30M to advance its kidney stone treatment system. Find out how it could reshape ureteroscopy outcomes in 2026.
Why the Nanodropper–Bedo–Viseon merger could reset the rules of personalized eyecare
Mu Medical unites Nanodropper, Bedo, and Viseon into a precision eyecare platform. Find out what this could mean for the future of AI-led ophthalmology.
Phanes’ spevatamig shows 40% response rate in mPDAC: How it compares to GnP standard
Phanes’ spevatamig + chemo combo shows 40% ORR in mPDAC. Find out why this bispecific antibody may change frontline pancreatic cancer treatment.